Exact Sciences — Jul 31, 2024 release

msmulevitz@exactsciences.com 608-345-8010   For Immediate Release   Exact Sciences Announces Second-Quarter 2024 Results   Reports record results, screened more than 1 million people with Cologuard ® , raises adjusted EBITDA guidance Second quarter highlights • Delivered total second quarter revenue of $699 million, an increase of 12%, or 13% on a core revenue basis, including Screening revenue of $532 million and Precision Oncology revenue of $168 million • Screened more than 1 million people with Cologuard for the first time during a quarter and tested a record number of cancer patients with Oncotype DX ® • Advanced pipeline by generating evidence supporting molecular residual disease, multi-cancer screening, and blood-based colorectal cancer screening tests • Maintains full-year 2024 revenue guidance and raises full-year adjusted EBITDA guidance midpoint by $8M MADISON, Wis. , July 31, 2024 — Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $699 million for the second quarter ended June 30, 2024, compared to $622 million for the same period of 2023.   “Our second quarter results show the dedication of Exact Sciences' world-class team and the power of our unique platform,” said Kevin Conroy, chairman and CEO. “We delivered answers to more patients and healthcare professionals than ever before, achieved record revenue and profitability, and advanced each of our key pipeline programs. Momentum continues to build, fueling our purpose to help eradicate cancer.” Second-quarter 2024 financial results For the three-month period ended June 30, 2024, as compared to the same period of 2023 (where applicable): • Total revenue was $699 million, an increase of 12 percent or 13 percent on a core revenue basis • Screening revenue was $532 million, an increase of 15 percent • Precision Oncology revenue was $168 million, an increase of 7 percent, or 6 percent on a core revenue basis • Gross margin including amortization of acquired intangible assets was